Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

Video

James Weitzman, MD, discusses sequencing challenges in multiple myeloma treatment.

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

It is an amazing time for patients with multiple myeloma because so many options are available, says Weitzman. However, with these advances come new challenges because now the field is trying to stay ahead of the data that are rapidly being reported and stay caught up with the guidelines on how to best use these agents.

It is important to stay a step ahead in order to provide patients with the best treatment possible, says Weitzman. Some questions that arise include: What agents should be used in the frontline setting? How can they be combined? Upon relapse, should patients be treated immediately or should they wait for symptomatic relapse? What agents should be used and when can they be reused? What agents combined with each other can have synergy? These are challenging yet exciting questions, says Weitzman. The field is constantly learning and discovering new ways to improve outcomes for patients with multiple myeloma, concludes Weitzman.

Related Videos
Francesco Di Meo, PhD
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Danai Dima, MD
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ariel Grajales-Cruz, MD, assistant member, Department of Malignant Hematology, Multiple Myeloma Section, Moffitt Cancer Center; assistant professor, University of South Florida
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Joseph Mikhael, MD
Ariel F. Grajales-Cruz, MD, Moffitt Cancer Center